Abstract
In Reply. — We are pleased to respond to the questions about Questran raised by Dr Goldstein by assuring him that (1) the cholestyramine resin used in the Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) was not contaminated, (2) currently marketed Questran is free of contamination, and (3) although a temporal association between cholestyramine resin and certain tumors has been observed, a causal relationship has not been established after more than 20 years of commercial availability and several hundred thousand patient-years of therapy dispensed. The questions asked by Dr Goldstein appear to arise from the fact that, in April 1988, Bristol Laboratories initiated a recall because it determined that certain batches of bulk cholestyramine resin supplied by Rohm & Haas and used in the production of Questran contained very low levels of the agricultural chemicals dichlorodiphenyldichloroethylene and dichlorobenzophenone. These chemicals are related to the manufacture of a pesticide (dicofol)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
